Influence of @entity6906 polymorphism on maintenance therapy for XXXX .

@entity1 @entity17710 @entity137 @entity981 @entity9769 @entity6822 @entity7275 @entity5906 @entity6906 @entity4446 @entity36620 @entity26816 @entity1778 @entity3929 @entity1762 @entity12859 @entity1499
BACKGROUND: A management of adverse effect of chemotherapy is essential to improve outcome of @entity1 with @entity1778 . Some kind of genetic polymorphisms can predict treatment-related @entity137 , and be used individually as bases of dose modifications for @entity4446 ( @entity7275 ) and @entity1499 ( @entity6822 ) in maintenance therapy for childhood @entity981 ( @entity981 ). We investigate associations between clinical course and polymorphisms of candidate genes which have not been less evaluated in Japanese @entity1 . METHODS: Fifty-three @entity1 who received maintenance chemotherapy were enrolled to this study. The scheduled dose of oral @entity7275 was 40   mg/m(2) daily and that of oral @entity6822 was 25   mg/m(2) weekly. The doses were adjusted taking into account the @entity1 ' @entity1762 blood cell (WBC) count (target range: 2.5 to 3.5   *   10(9) /L) and @entity5906 aminotransferase (AST) and @entity3929 aminotransferase (ALT) levels under 750   IU/L. Eight polymorphisms in 6 candidate genes, @entity17710 , ITPA, @entity36620 , @entity9769 , @entity12859 , and @entity6906 were genotyped by Taqman PCR method. Clinical course was reviewed from the @entity1 ' medical records retrospectively. RESULTS: The average dose of @entity7275 was lower in the @entity1 with at least one variant allele at @entity6906 @entity26816 than in the @entity1 with wild homozygous genotype. The other analyzed polymorphisms were not associated with @entity137 or doses of @entity7275 and @entity6822 . CONCLUSIONS: Polymorphism of @entity6906 @entity26816 could be a strong predictor of dose reduction of @entity7275 in maintenance chemotherapy in childhood @entity981 .
